|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2008-3-25
|
|
pubmed:abstractText |
The positive regulatory domain I (PRDM1) is a master regulator of terminal B-cell differentiation. However, PRDM1 is not B-cell specific. To determine its role in T-cell lymphoma, PRDM1 expression was investigated in 60 patients. PRDM1alpha and PRDM1beta transcripts were detected in laser-microdissected T-lymphoma cells in 27 and 14 patients, respectively, mostly in cases with IRF4 expression. PRDM1beta was associated with increased c-MYC expression. PRDM1beta-positive patients displayed advanced Ann Arbor stage and high-risk International Prognostic Index and were linked to short survival times. In vitro, PRDM1beta was related to resistance to chemotherapeutic agents and could be down-regulated by the proteasome inhibitor bortezomib. Kinetic studies showed that bortezomib down-regulation of PRDM1beta preceded decreased IRF4 and c-MYC expression. An earlier retaining of cytoplasmic IkappaBalpha in bortezomib-treated cells was revealed, concomitant with blockade of NF-kappaB nuclear translocation. These results demonstrate the involvement of PRDM1beta in T-cell lymphoma, with possible therapeutic interference by the proteasome inhibitor.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Boronic Acids,
http://linkedlifedata.com/resource/pubmed/chemical/I-kappa B Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon Regulatory Factors,
http://linkedlifedata.com/resource/pubmed/chemical/MYC protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/NF-kappaB inhibitor alpha,
http://linkedlifedata.com/resource/pubmed/chemical/PRDM1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Protease Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Proteasome Endopeptidase Complex,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-myc,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrazines,
http://linkedlifedata.com/resource/pubmed/chemical/Repressor Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Transcription Factors,
http://linkedlifedata.com/resource/pubmed/chemical/bortezomib,
http://linkedlifedata.com/resource/pubmed/chemical/interferon regulatory factor-4
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0006-4971
|
|
pubmed:author |
pubmed-author:ChenSai-JuanSJ,
pubmed-author:FealCC,
pubmed-author:GarciaJosé-FranciscoJF,
pubmed-author:JaninAnneA,
pubmed-author:LeboeufChristopheC,
pubmed-author:LiJun-MinJM,
pubmed-author:LiuYan-YanYY,
pubmed-author:LobMM,
pubmed-author:ShenZhi-XiangZX,
pubmed-author:SongYong-PingYP,
pubmed-author:WangLiL,
pubmed-author:ZhangQun-LingQL,
pubmed-author:ZhangYi-WenYW,
pubmed-author:ZhaoWei-LiWL
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
111
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3867-71
|
|
pubmed:meshHeading |
pubmed-meshheading:18235046-Boronic Acids,
pubmed-meshheading:18235046-Down-Regulation,
pubmed-meshheading:18235046-Drug Resistance, Neoplasm,
pubmed-meshheading:18235046-Gene Expression Regulation, Leukemic,
pubmed-meshheading:18235046-Humans,
pubmed-meshheading:18235046-I-kappa B Proteins,
pubmed-meshheading:18235046-Interferon Regulatory Factors,
pubmed-meshheading:18235046-Lymphoma, T-Cell,
pubmed-meshheading:18235046-Microdissection,
pubmed-meshheading:18235046-Neoplasm Staging,
pubmed-meshheading:18235046-Protease Inhibitors,
pubmed-meshheading:18235046-Proteasome Endopeptidase Complex,
pubmed-meshheading:18235046-Proto-Oncogene Proteins c-myc,
pubmed-meshheading:18235046-Pyrazines,
pubmed-meshheading:18235046-Repressor Proteins,
pubmed-meshheading:18235046-Survival Rate,
pubmed-meshheading:18235046-Transcription Factors
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor.
|
|
pubmed:affiliation |
State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, China.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
